NGAL in trans-catheter aortic valve implantation on and off renalguard

Sapir Sadon, Yaron Arbel*, Ariel Banai, Keren Lee Rozenfeld, Phillipe Taieb, Aviram Hochstadt, Yacov Shacham, Shmuel Banai, Ariel Finkelstein, Ilan Merdler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Introduction: Acute kidney injury (AKI) is a well-known complication post invasive cardiac procedures. RenalGuard system has been shown to reduce the risk of AKI in high-risk patients by evacuating iodine-based contrast material rapidly. Neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein stored in granules of mature neutrophils and is released to the blood stream due to acute tubular damage. This report examined the biomarker as a sub study of the randomized sham control study REDUCE-AKI in the setting of Trans-Aortic Valve Implantation (TAVI). Methods: Venous blood was drawn from 27 patients. Blood was drawn at designated time intervals: before the procedure, after 12 hours and after 24 hours. Patients were randomly allocated to active versus sham RenalGuard activity. Results: There was no difference between baseline and 24 hours levels in NGAL values (ng/mL) in the sham group (median 70.3 IQ 21.5, 176.6) versus the active group (median 46.9, IQR 1.3, 127.7) (P = 0.259). There was also no association between NGAL and clinical complications. Conclusion: Forced diuresis with matched hydration does not prevent AKI in patients undergoing TAVI and measuring NGAL correlates with these findings.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalSigna Vitae
Issue number4
StatePublished - Jul 2021


  • AKI
  • NGAL
  • RenalGuard
  • TAVI
  • TAVR


Dive into the research topics of 'NGAL in trans-catheter aortic valve implantation on and off renalguard'. Together they form a unique fingerprint.

Cite this